{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:34:31Z","timestamp":1792809271655,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":1548,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","fertstert.org","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.fertnstert.2018.01.013","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T14:41:49Z","timestamp":1521470509000},"page":"398-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":214,"title":["Role of medical therapy in the management of uterine adenomyosis"],"prefix":"10.1016","volume":"109","author":[{"given":"Silvia","family":"Vannuccini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7277-6420","authenticated-orcid":false,"given":"Flavia","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-625X","authenticated-orcid":false,"given":"Felice","family":"Petraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2018.01.013_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bpobgyn.2016.09.006","article-title":"Adenomyosis and Abnormal Uterine Bleeding (AUB-A)\u2014Pathogenesis, diagnosis, and management","volume":"40","author":"Abbott","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib2","doi-asserted-by":"crossref","first-page":"248.e1","DOI":"10.1016\/j.ajog.2013.06.006","article-title":"The uterine junctional zone: A 3-dimensional ultrasound study of patients with endometriosis","volume":"209","author":"Exacoustos","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.bpobgyn.2014.04.010","article-title":"Imaging for the evaluation of endometriosis and adenomyosis","volume":"28","author":"Exacoustos","year":"2014","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/uog.14806","article-title":"Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: A consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group","volume":"46","author":"Van Den Bosch","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bpobgyn.2006.01.006","article-title":"The symptomatology of adenomyosis","volume":"20","author":"Peric","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib6","first-page":"127","article-title":"Current and future medical treatment of adenomyosis","volume":"8","author":"Tosti","year":"2016","journal-title":"J Endometr"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/uog.14834","article-title":"Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: Association with symptoms","volume":"46","author":"Pinzauti","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib8","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/humrep\/des332","article-title":"How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic","volume":"27","author":"Naftalin","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib9","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/humrep\/dex088","article-title":"Relationship between the magnetic resonance imaging appearance of adenomyosis and endometriosis phenotypes","volume":"32","author":"Chapron","year":"2017","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12958-016-0185-6","article-title":"Adenomyosis in infertile women: prevalence and the role of 3D ultrasound as a marker of severity of the disease","volume":"14","author":"Puente","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/humrep\/deq034","article-title":"Characteristics indicating adenomyosis coexisting with leiomyomas: A case-control study","volume":"25","author":"Taran","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/1933719114522520","article-title":"Preoperative and Postoperative Clinical and Transvaginal Ultrasound Findings of Adenomyosis in Patients With Deep Infiltrating Endometriosis","volume":"21","author":"Lazzeri","year":"2014","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib13","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.rbmo.2017.06.016","article-title":"Pathogenesis of adenomyosis: An update on molecular mechanisms","volume":"35","author":"Vannuccini","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.bpobgyn.2007.07.006","article-title":"Hormonal treatments for adenomyosis","volume":"22","author":"Fedele","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib15","first-page":"1","article-title":"Adenomyosis: a systematic review of medical treatment","volume":"3590","author":"Pontis","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib16","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1093\/humrep\/deq240","article-title":"Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma","volume":"25","author":"Khan","year":"2010","journal-title":"Hum Reprod"},{"issue":"3 Suppl. 1","key":"10.1016\/j.fertnstert.2018.01.013_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0015-0282(02)04813-6","article-title":"Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas","volume":"79","author":"Ishihara","year":"2003","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/humrep\/dep437","article-title":"Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy","volume":"25","author":"Khan","year":"2010","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib19","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1093\/humrep\/15.12.2512","article-title":"GnRH agonist-suppressed expression of nitric oxide synthases and generation of peroxynitrite in adenomyosis","volume":"15","author":"Kamada","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib20","first-page":"538","article-title":"Treatment of adenomyosis with long-term GnRH analogues: A case report","volume":"78","author":"Grow","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2016.10.053","article-title":"Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis","volume":"207","author":"Takeuchi","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib22","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0015-0282(16)55704-5","article-title":"Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: A case report","volume":"59","author":"Nelson","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib23","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1517\/14656566.2014.953055","article-title":"An update on the pharmacological management of adenomyosis","volume":"15","author":"Streuli","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib24","first-page":"CR1","article-title":"Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis","volume":"15","author":"Akira","year":"2009","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib25","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.fertnstert.2011.06.048","article-title":"Progestins inhibit estradiol-induced vascular endothelial growth factor and stromal cell-derived factor 1 in human endometrial stromal cells","volume":"96","author":"Okada","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib26","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/ph5101120","article-title":"Norethindrone acetate in the medical management of adenomyosis","volume":"5","author":"Muneyyirci-Delale","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/0002-9378(75)90499-8","article-title":"Danazol: an antigonadotropic agent in the treatment of pelvic endometriosis","volume":"123","author":"Lauersen","year":"1975","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib28","first-page":"241","article-title":"Danazol: molecular, endocrine, and clinical pharmacology","volume":"323","author":"Barbieri","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib29","first-page":"CD001017","article-title":"Danazol for heavy menstrual bleeding","author":"Beaumont","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/01.pgp.0000130109.80359.57","article-title":"Expression of apoptosis-related proteins in adenomyotic uteri treated with danazol and GnRH agonists","volume":"23","author":"Ueki","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib31","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0015-0282(16)59408-4","article-title":"Immunosuppressive effects of danazol in\u00a0vitro","volume":"48","author":"Hill","year":"1987","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0015-0282(16)56821-6","article-title":"Effect of danazol in\u00a0vitro and in\u00a0vivo on monocyte-mediated enhancement of endometrial cell proliferation in women with endometriosis","volume":"62","author":"Braun","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0002-9378(11)91433-1","article-title":"Effects of danazol at the immunologic level in patients with adenomyosis, with special reference to autoantibodies: a multi-center cooperative study","volume":"167","author":"Ota","year":"1992","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1447-0756.1990.tb00207.x","article-title":"A New Therapy for Pelvic Endometriosis and Uterine Adenomyosis: Local Effect of Vaginal and Intrauterine Danazol Application","volume":"16","author":"Igarashi","year":"1990","journal-title":"Asia Oceania J Obstet Gynaecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000292410","article-title":"Danazol suspension injected into the uterine cervix of patients with adenomyosis and myoma. Preliminary study","volume":"39","author":"Takebayashi","year":"1995","journal-title":"Gynecol Obstet Investig"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0015-0282(00)00624-5","article-title":"Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device","volume":"74","author":"Igarashi","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib37","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/humrep\/den208","article-title":"Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model","volume":"23","author":"Zhang","year":"2008","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib38","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.fertnstert.2008.08.017","article-title":"Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age","volume":"92","author":"Luisi","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5301\/je.5000270","article-title":"Long-term vaginal danazol treatment in fertile age women with adenomyosis","volume":"9","author":"Tosti","year":"2017","journal-title":"J Endometr Pelvic Pain Disord"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib40","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.steroids.2007.10.003","article-title":"Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile","volume":"73","author":"Sasagawa","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00044011-199918040-00003","article-title":"Influence of dienogest on ovulation in young fertile women","volume":"18","author":"Moore","year":"1999","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejogrb.2014.05.031","article-title":"Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells","volume":"179","author":"Yamanaka","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib43","first-page":"279","article-title":"The Effects of Dienogest on Macrophage and Natural Killer Cells in Adenomyosis: A Randomized Controlled Study","volume":"11","author":"Prathoomthong","year":"2018","journal-title":"Int J Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3109\/09513590.2014.926882","article-title":"Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study","volume":"30","author":"Hirata","year":"2014","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib45","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.fertnstert.2017.07.021","article-title":"Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study","volume":"108","author":"Osuga","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/jog.13406","article-title":"Long-term use of dienogest in the treatment of painful symptoms in adenomyosis","volume":"43","author":"Osuga","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib47","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1447-0756.2011.01778.x","article-title":"Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest","volume":"38","author":"Nagata","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib48","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s00404-015-3755-5","article-title":"Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial","volume":"292","author":"Fawzy","year":"2015","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib49","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2010.05.005","article-title":"Non-contraceptive health benefits of intrauterine hormonal systems","volume":"82","author":"Fraser","year":"2010","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/09513590.2017.1334198","article-title":"Non-contraceptive benefits of intrauterine levonorgestrel administration: why not?","volume":"33","author":"Sabbioni","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib51","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0015-0282(97)00245-8","article-title":"Treatment of adenomyosis-associated menorrhagia with a levonorgestrel- releasing intrauterine device","volume":"68","author":"Fedele","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.contraception.2012.04.001","article-title":"Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis","volume":"86","author":"Kelekci","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib53","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1093\/humrep\/16.10.2103","article-title":"Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium","volume":"16","author":"Maruo","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib54","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/humrep\/13.5.1210","article-title":"Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system","volume":"13","author":"Critchley","year":"1998","journal-title":"Hum Reprod"},{"issue":"sup2","key":"10.1016\/j.fertnstert.2018.01.013_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/09513590.2016.1232673","article-title":"Treatment strategies for pelvic pain associated with adenomyosis","volume":"32","author":"Radzinsky","year":"2016","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.contraception.2008.11.004","article-title":"The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis","volume":"79","author":"Sheng","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib57","doi-asserted-by":"crossref","first-page":"373.e1","DOI":"10.1016\/j.ajog.2007.10.798","article-title":"Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis","volume":"198","author":"Cho","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib58","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/humrep\/deg179","article-title":"Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis","volume":"18","author":"Laoag-Fernandez","year":"2003","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib59","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.fertnstert.2010.10.009","article-title":"Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis","volume":"95","author":"Ozdegirmenci","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib60","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejogrb.2013.07.019","article-title":"Effects of the levonorgestrel-releasing intrauterine system on urinary symptoms in patients with adenomyosis","volume":"170","author":"Ekin","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib61","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000351431","article-title":"Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis","volume":"22","author":"Zhang","year":"2013","journal-title":"Med Princ Pract"},{"issue":"4","key":"10.1016\/j.fertnstert.2018.01.013_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.contraception.2015.05.015","article-title":"Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: A randomized clinical trial","volume":"92","author":"Shaaban","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00404-016-4105-y","article-title":"Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis","volume":"294","author":"Lee","year":"2016","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/09513590802005562","article-title":"Non-contraceptive use of hormonal contraceptives","volume":"24","author":"Schindler","year":"2008","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib65","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/09513590601005375","article-title":"Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis","volume":"22","author":"Maia","year":"2006","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib66","first-page":"CD001751","article-title":"Nonsteroidal anti-inflammatory drugs for dysmenorrhoea","author":"Marjoribanks","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib67","first-page":"CD000400","article-title":"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding","volume":"1","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib68","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1095\/biolreprod57.3.514","article-title":"Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium","volume":"57","author":"Kitawaki","year":"1997","journal-title":"Biol Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib69","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/0002-9378(93)90654-2","article-title":"Evidence for estrogen synthesis in adenomyotic tissues","volume":"169","author":"Yamamoto","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib70","doi-asserted-by":"crossref","first-page":"1468.e9","DOI":"10.1016\/j.fertnstert.2006.09.010","article-title":"Concomitant treatment of severe uterine adenomyosis in a premenopausal woman with an aromatase inhibitor and a gonadotropin-releasing hormone agonist","volume":"87","author":"Kimura","year":"2007","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib71","first-page":"489","article-title":"Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial. Acta Obstet Gynecol","volume":"91","author":"Badawy","year":"2012","journal-title":"Scand"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib72","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/GCO.0000000000000082","article-title":"Selective progesterone receptor modulators","volume":"26","author":"Whitaker","year":"2014","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib73","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14728222.2016.1180368","article-title":"Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies","volume":"20","author":"Wagenfeld","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib74","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.fertnstert.2011.08.021","article-title":"Selective progesterone receptor modulators in reproductive medicine: Pharmacology, clinical efficacy and safety","volume":"96","author":"Bouchard","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib75","doi-asserted-by":"crossref","first-page":"154","DOI":"10.12891\/ceog15872014","article-title":"The influence of mifepristone to caspase 3 expression in adenomyosis","volume":"41","author":"Wang","year":"2014","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib76","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0015-0282(16)58022-4","article-title":"Treatment of endometriosis with the antiprogesterone mifepristone (RU486)","volume":"65","author":"Kettel","year":"1996","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib77","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib78","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa1700089","article-title":"Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist","volume":"377","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib79","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.fertnstert.2017.01.013","article-title":"Partial suppression of estradiol: a new strategy in endometriosis management?","volume":"107","author":"Donnez","year":"2017","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib80","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000336409","article-title":"Elevated immunoreactivity against class i histone deacetylases in adenomyosis","volume":"74","author":"Liu","year":"2012","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib81","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.fertnstert.2006.11.009","article-title":"A pilot study on the off-label use of valproic acid to treat adenomyosis","volume":"89","author":"Liu","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib82","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1177\/1933719110373807","article-title":"Valproic acid as a therapy for adenomyosis: a comparative case series","volume":"17","author":"Liu","year":"2010","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib83","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1447-0756.2011.01655.x","article-title":"Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis","volume":"37","author":"Liu","year":"2011","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib84","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/1933719111404610","article-title":"The Retardation of Myometrial Infiltration, Reduction of Uterine Contractility, and Alleviation of Generalized Hyperalgesia in Mice With Induced Adenomyosis by Levo-Tetrahydropalmatine (l -THP) and Andrographolide","volume":"18","author":"Mao","year":"2011","journal-title":"Reprod Sci"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib85","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/humrep\/dev025","article-title":"Platelets are an unindicted culprit in the development of endometriosis: Clinical and experimental evidence","volume":"30","author":"Ding","year":"2015","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib86","first-page":"355","article-title":"Transforming growth factor \u03b21 signaling coincides with epithelial-mesenchymal transition and fibroblast-to-myofibroblast transdifferentiation in the development of adenomyosis in mice","volume":"31","author":"Shen","year":"2016","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib87","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12958-016-0198-1","article-title":"Anti-platelet therapy holds promises in treating adenomyosis: experimental evidence","volume":"14","author":"Zhu","year":"2016","journal-title":"Reprod Biol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1093\/humupd\/dmt052","article-title":"Structural and molecular features of the endomyometrium in endometriosis and adenomyosis","volume":"20","author":"Benagiano","year":"2014","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.rbmo.2011.10.003","article-title":"Adenomyosis and infertility","volume":"24","author":"Campo","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib90","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0015-0282(00)00411-8","article-title":"Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist","volume":"73","author":"Wang","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib91","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0015-0282(16)55703-3","article-title":"Pregnancy after medical therapy of adenomyosis with a gonadotropin-releasing hormone agonist","volume":"59","author":"Hirata","year":"1993","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib92","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0015-0282(16)56471-1","article-title":"Live birth after treatment of severe adenomyosis with a gonadotropin-releasing hormone agonist","volume":"61","author":"Silva","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib93","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tjog.2012.04.008","article-title":"Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH agonist: Long-term follow-up in a series of nine patients","volume":"51","author":"Huang","year":"2012","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib94","first-page":"260","article-title":"Live birth after conservative surgery for severe adenomyosis following magnetic resonance imaging and gonadotropin-releasing hormone agonist therapy","volume":"44","author":"Ozaki","year":"1999","journal-title":"Int J Fertil Womens Med"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib95","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/humupd\/dmg010","article-title":"Uterine adenomyosis in the infertility clinic","volume":"9","author":"Devlieger","year":"2003","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib96","first-page":"442","article-title":"Gonadotropin-releasing hormone agonists and laparoscopy in the treatment of adenomyosis with infertility","volume":"113","author":"Lin","year":"2000","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib97","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejogrb.2010.02.047","article-title":"Adenomyosis has no adverse effects on IVF\/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF\/ICSI","volume":"151","author":"Mijatovic","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib98","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3109\/09513590.2013.824960","article-title":"Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis","volume":"29","author":"Niu","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib99","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5653\/cerm.2016.43.3.169","article-title":"Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment","volume":"43","author":"Park","year":"2016","journal-title":"Clin Exp Reprod Med"},{"key":"10.1016\/j.fertnstert.2018.01.013_bib100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fertnstert.2017.06.025","article-title":"Effects of adenomyosis on in\u00a0vitro fertilization treatment outcomes: a meta-analysis","volume":"108","author":"Younes","year":"2017","journal-title":"Fertil Steril"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821830013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001502821830013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T07:25:10Z","timestamp":1666509910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001502821830013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S001502821830013X"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.01.013","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of medical therapy in the management of uterine adenomyosis","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2018.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92018 American Society for Reproductive Medicine, Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}